Moderna, Inc. (NASDAQ:MRNA) ranks among the best biotech stocks to buy. Following solid trial results for Moderna, Inc.
US health technology body ICER will review the comparative clinical effectiveness and value of four COVID-19 vaccines: Pfizer ...
Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...
This photo provided by Pfizer in August 2025 shows a vial of the updated COVID-19 vaccine Comirnaty. (Pfizer via AP) Show more Show less This photo provided by Pfizer in August 2025 shows a vial of ...
A new report from Portland State University found that budget cuts under President Donald Trump's new spending bill threaten ...
A lawyer for Texas death row inmate Robert Roberson says he will not petition for clemency ahead of his scheduled execution ...
Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...
Moderna said on Tuesday its updated COVID-19 vaccine elicited a strong immune response in all adults age 65 and older, as ...
The updated formula for Moderna’s COVID-19 vaccine generates a 16-fold increase in antibodies neutralize the intended SARS-CoV-2 variant.
Respiratory Virus Season (RVS) refers to the peak period of hospitalizations and deaths from respiratory viruses such as ...
US mRNA specialist Moderna today announced positive preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback